论文部分内容阅读
目的:分析瑞舒伐他汀在治疗急性冠状动脉综合征伴高脂血症过程中药物的临床疗效及安全性。方法:随机抽取2009—2010年期间患急性冠状动脉综合征伴高脂血症的患者90例,对患者进行瑞舒伐他汀药物治疗,观察患者进行治疗前后各项指标的变化。结果:相对于治疗前,治疗后患者TC、LDL-C以及脂蛋白(Lp)(a)的血清浓度有所下降,而HDL-C上升,差异有统计学意义,P<0.05。结论:瑞舒伐他汀在治疗急性冠状动脉综合征伴高脂血症过程中有一定的临床疗效及安全性
Objective: To analyze the clinical efficacy and safety of rosuvastatin in the treatment of acute coronary syndrome with hyperlipidemia. Methods: Ninety patients with acute coronary syndrome and hyperlipidemia were randomly selected from 2009 to 2010. The patients were treated with rosuvastatin, and the changes of the indexes before and after treatment were observed. Results: The serum concentrations of TC, LDL-C and Lp (a) decreased compared with those before treatment, while the HDL-C increased after treatment, with statistical significance (P <0.05). Conclusion: Rosuvastatin has certain clinical efficacy and safety in the treatment of acute coronary syndrome with hyperlipidemia